Title: Cognitive dysfunction in depression: the need for discovery, development and translation in this Domain

**Abstract**

Depression is a common, distressing and debilitating disorder, which is frequently chronic and relapsing. Depression is associated with problems in cold and hot cognition (Roiser et al, 2012; Roiser & Sahakian, 2013). These problems include impairments in sustained attention, forms of memory, planning and problem solving, decision-making, as well as negative attentional bias and over-sensitivity to negative feedback (Rock et al, 2013). Therefore, it is perhaps not surprising that workplace functionality is affected by depression, with both lost earnings due to absenteeism and lower productivity on return to work or presenteeism (Beddington et al, 2008). How can we improve the cognitive outcome for patients? Early detection of depression and early effective treatment should prevent or reduce the impact on cognition (Insel, Sahakian et al, 2012; Insel, Voon et al, 2013). Fast-acting medications targeting the glutamate system, especially the NMDA receptor, directly are currently in development (ketamine: Zarate et al, 2006). Recently approved drugs, such as vortioxetine, with multi-modal action have been shown to improve performance on some tests of cold cognitive function (Katona et al, 2012; McIntyre et al, 2014). It is concluded that cognition is an important target for treatment in depression (National Academies of Sciences, Engineering, and Medicine, 2015).
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